Apollo Scientific

Biosynth

Targetmol

Atezolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed death-ligand 1 (PD-L1). It is primarily used in the treatment of various cancers, including non-small cell lung cancer and urothelial carcinoma. The mechanism of action involves blocking the interaction between PD-L1 and its receptors, PD-1 and B7.1, thereby enhancing T-cell activation and promoting an immune response against tumor cells. Atezolizumab is administered via intravenous infusion and is characterized by its humanized IgG1 structure, which contributes to its stability and efficacy. The drug is typically associated with a range of potential side effects, including immune-related adverse events, due to its mechanism of enhancing immune activity. Its development represents a significant advancement in cancer immunotherapy, providing a therapeutic option for patients with advanced malignancies. As with all monoclonal antibodies, careful monitoring during treatment is essential to manage any adverse reactions effectively.

Atezolizumab

1380723-44-3: Atezolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed death-ligand 1 (PD-L1). It is primarily used in the treatment of various cancers, including non-small cell lung cancer and urothelial carcinoma. The mechanism of action involves blocking the interaction between PD-L1 and its receptors, PD-1 and B7.1, thereby enhancing T-cell activation and promoting an immune response against tumor cells. Atezolizumab is administered via intravenous infusion and is characterized by its humanized IgG1 structure, which contributes to its stability and efficacy. The drug is typically associated with a range of potential side effects, including immune-related adverse events, due to its mechanism of enhancing immune activity. Its development represents a significant advancement in cancer immunotherapy, providing a therapeutic option for patients with advanced malignancies. As with all monoclonal antibodies, careful monitoring during treatment is essential to manage any adverse reactions effectively.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1. Atezolizumab has antitumor effect. Cost-effective and quality-assured.

<p>Monoclonal antibody against PDL-1; anti-cancer agent</p>

CAS 1380723-44-3

Atezolizumab

Atezolizumab

Ref: 54-OR1139613

Atezolizumab

Ref: TM-T9902

Atezolizumab

Ref: 3D-BA165584